secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001193125-24-000991
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics announces positive initial clinical data from ACHIEVE and DELIVER trials
--------------------------------------------------------------------------------

- DYNE-101 in ACHIEVE trial: 19% mean splicing correction at 3.4 mg/kg at 3 months; 3.8 sec myotonia benefit at 1.8 mg/kg at 6 months.
- DYNE-251 in DELIVER trial: 0.88% mean dystrophin expression at 5 mg/kg at 6 months, exceeding eteplirsen with 24-fold lower dose.
- Favorable safety profiles: no related serious adverse events; dose escalation to 6.8 mg/kg (ACHIEVE) and 40 mg/kg (DELIVER) supported.
- Company plans to initiate registrational cohorts for both programs by end of 2024, with next data updates in second half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524000991/0001193125-24-000991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524000991/d586587d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-000991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer